Business Wire
15 Jun 2026, 20:01 UTC · 14w ago
Verdict
Headline takes no side. We score VSTM +0.20 across two claims — slightly bullish.
+0.20slightly bullish
More positive than 49% of ticker scores this week
What the story claims
2 claims · scored −1 bearish … +1 bullish
Verastem Oncology will report updated Phase 1/2 TARGET-D 101 data for its oral KRAS G12D inhibitor VS-7375.
So whatClinical trial data for a targeted oncology asset is a primary driver of valuation and volatility for small-cap biotech firms.
More positive than 92% of claims this week
The company will provide a progress report across the broader VS-7375 TARGET-D program.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
More positive than 62% of claims this week
Which stocks this story touches
More positive than 49% of ticker scores this week
The company is announcing upcoming progress reports and data updates for its clinical program.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
+99.8%
Price agrees with the score
$7.99 vs $4.00 close before publication (Jun 15) · not market-adjusted
VSTM chart →
